Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis

Journal of Hepatology

Volumn 53, Issue 6, 2010, Pages 1059-1068

  Olleros, Maria L ^a   Vesin, Dominique ^a   Fotio, Agathe L ^a   Santiago Raber, Marie Laure ^a   Tauzin, Sébastien ^a   Szymkowski, David E ^b   Garcia, Irene ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Xencor Inc   (United States)

Author keywords

BCG liver granulomas; Liver injury; Membrane TNF; Soluble TNF

Indexed keywords

ACTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BCG VACCINE; CYTOKINE; ETANERCEPT; FC RECEPTOR; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GRANULOMA; HEPATITIS; LIVER INJURY; LIVER PROTECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; DRUG-INDUCED LIVER INJURY; GRANULOMA; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MYCOBACTERIUM BOVIS; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78049458674     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.05.029     Document Type: Article

References (47)

1. K.K. Tan, K. Chen, and R. Sim The spectrum of abdominal tuberculosis in a developed country: a single institution's experience over 7 years J Gastrointest Surg 13 2009 142 147
2. U. Drebber, H.U. Kasper, J. Ratering, I. Wedemeyer, P. Schirmacher, and H.P. Dienes Hepatic granulomas: histological and molecular pathological approach to differential diagnosis - a study of 442 cases Liver Int 28 2008 828 834
3. C. Abramowsky, B. Gonzalez, and R.U. Sorensen Disseminated bacillus Calmette-Guerin infections in patients with primary immunodeficiencies Am J Clin Pathol 100 1993 52 56
4. J.L. Casanova, S. Blanche, J.F. Emile, E. Jouanguy, S. Lamhamedi, and F. Altare Idiopathic disseminated bacillus Calmette-Guerin infection: a French national retrospective study Pediatrics 98 1996 774 778
5. F.W. Leebeek, R.J. Ouwendijk, A.H. Kolk, A. Dees, J.C. Meek, and J.E. Nienhuis Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation Gut 38 1996 616 618
6. H. Koga, M. Kuroda, S. Kudo, A. Yamaguchi, M. Usami, and T. Suzuki Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder Int J Urol 12 2005 145 151
7. B.M. Saunders, and W.J. Britton Life and death in the granuloma: immunopathology of tuberculosis Immunol Cell Biol 85 2007 103 111
8. H. Tilg, and A.M. Diehl Cytokines in alcoholic and nonalcoholic steatohepatitis N Engl J Med 343 2000 1467 1476
9. R.A. Black, C.T. Rauch, C.J. Kozlosky, J.J. Peschon, J.L. Slack, and M.F. Wolfson A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 1997 729 733
10. M.L. Olleros, R. Guler, N. Corazza, D. Vesin, H.P. Eugster, and G. Marchal Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha J Immunol 168 2002 3394 3401
11. S. Kobayashi, J. Nishihira, S. Watanabe, and S. Todo Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette-Guerin and lipopolysaccharide Hepatology 29 1999 1752 1759
12. R. Guler, M.L. Olleros, D. Vesin, R. Parapanov, C. Vesin, and S. Kantengwa Inhibition of inducible nitric oxide synthase protects against liver injury induced by mycobacterial infection and endotoxins J Hepatol 41 2004 773 781
13. L.G. Criscione, and E.W. St. Clair Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases Curr Opin Rheumatol 14 2002 204 211
14. D. Tracey, L. Klareskog, E.H. Sasso, J.G. Salfeld, and P.P. Tak Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 2008 244 279
15. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 2001 1098 1104
16. E.C. Keystone, A.F. Kavanaugh, J.T. Sharp, H. Tannenbaum, Y. Hua, and L.S. Teoh Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial Arthritis Rheum 50 2004 1400 1411
17. S. Naveau, S. Chollet-Martin, S. Dharancy, P. Mathurin, P. Jouet, and M.A. Piquet A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis Hepatology 39 2004 1390 1397
18. N.C. Boetticher, C.J. Peine, P. Kwo, G.A. Abrams, T. Patel, and B. Aqel A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis Gastroenterology 135 2008 1953 1960
19. S. Ehlers Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF Ann Rheum Dis 62 2003 ii37 ii42
20. C. Fremond, N. Allie, I. Dambuza, S.I. Grivennikov, V. Yeremeev, and V.F. Quesniaux Membrane TNF confers protection to acute mycobacterial infection Respir Res 6 2005 136
21. M.L. Olleros, D. Vesin, A.F. Lambou, J.P. Janssens, B. Ryffel, and S. Rose Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette-Guerin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis J Infect Dis 199 2009 1053 1063
22. C. Galanos, M.A. Freudenberg, and W. Reutter Galactosamine-induced sensitization to the lethal effects of endotoxin Proc Natl Acad Sci USA 76 1979 5939 5943
23. S.R. Ruuls, R.M. Hoek, V.N. Ngo, T. McNeil, L.A. Lucian, and M.J. Janatpour Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation Immunity 15 2001 533 543
24. I. Garcia, Y. Miyazaki, K. Araki, M. Araki, R. Lucas, and G.E. Grau Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections Eur J Immunol 25 1995 2401 2407
25. R. Guler, M.L. Olleros, D. Vesin, R. Parapanov, and I. Garcia Differential effects of total and partial neutralization of tumor necrosis factor on cell-mediated immunity to Mycobacterium bovis BCG infection Infect Immun 73 2005 3668 3676
26. M.W. Marino, A. Dunn, D. Grail, M. Inglese, Y. Noguchi, and E. Richards Characterization of tumor necrosis factor-deficient mice Proc Natl Acad Sci USA 94 1997 8093 8098
27. P.M. Steed, M.G. Tansey, J. Zalevsky, E.A. Zhukovsky, J.R. Desjarlais, and D.E. Szymkowski Inactivation of TNF signaling by rationally designed dominant-negative TNF variants Science 301 2003 1895 1898
28. J. Zalevsky, T. Secher, S.A. Ezhevsky, L. Janot, P.M. Steed, and C. O'Brien Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection J Immunol 179 2007 1872 1883
29. A. Morikawa, Y. Kato, T. Sugiyama, N. Koide, D. Chakravortty, and T. Yoshida Role of nitric oxide in lipopolysaccharide-induced hepatic injury in d-galactosamine-sensitized mice as an experimental endotoxic shock model Infect Immun 67 1999 1018 1024
30. G. Sass, S. Heinlein, A. Agli, R. Bang, J. Schumann, and G. Tiegs Cytokine expression in three mouse models of experimental hepatitis Cytokine 19 2002 115 120
31. C.C. Solorzano, R. Ksontini, J.H. Pruitt, P.J. Hess, P.D. Edwards, and A. Kaibara Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor J Immunol 158 1997 414 419
32. I. Garcia, R. Guler, D. Vesin, M.L. Olleros, P. Vassalli, and Y. Chvatchko Lethal Mycobacterium bovis Bacillus Calmette Guerin infection in nitric oxide synthase 2-deficient mice: cell-mediated immunity requires nitric oxide synthase 2 Lab Invest 80 2000 1385 1397
33. Garcia I, Olleros ML. The roles of tumor necrosis factor and other macrophage-derived cytokines in host defense mechanisms during the course of Mycobacterium tuberculosis infection. Current topics on the profiles of host immunological response to mycobacterial infections. In: Tomioka, editor. Research Singpost Special Immunol book; 2009.
34. D.V. Kuprash, M.B. Alimzhanov, A.V. Tumanov, A.O. Anderson, K. Pfeffer, and S.A. Nedospasov TNF and lymphotoxin beta cooperate in the maintenance of secondary lymphoid tissue microarchitecture but not in the development of lymph nodes J Immunol 163 1999 6575 6580
35. B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X.Y. Song, and D. Shealy Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2002 418 426
36. M. Nowak, G.C. Gaines, J. Rosenberg, R. Minter, F.R. Bahjat, and J. Rectenwald LPS-induced liver injury in d-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor Am J Physiol Regul Integr Comp Physiol 278 2000 R1202 R1209
37. N. Corazza, A. Badmann, and C. Lauer Immune cell-mediated liver injury Semin Immunopathol 31 2009 267 277
38. M.L. Olleros, R. Guler, D. Vesin, R. Parapanov, G. Marchal, and E. Martinez-Soria Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis Bacillus Calmette-Guerin and Mycobacterium tuberculosis infections Am J Pathol 166 2005 1109 1120
39. B.M. Saunders, S. Tran, S. Ruuls, J.D. Sedgwick, H. Briscoe, and W.J. Britton Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection J Immunol 174 2005 4852 4859
40. L. Alexopoulou, K. Kranidioti, S. Xanthoulea, M. Denis, A. Kotanidou, and E. Douni Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity Eur J Immunol 36 2006 2768 2780
41. J.W. Lu, H. Wang, J. Yan-Li, C. Zhang, H. Ning, and X.Y. Li Differential effects of pyrrolidine dithiocarbamate on TNF-alpha-mediated liver injury in two different models of fulminant hepatitis J Hepatol 48 2008 442 452
42. F. Hoffmann, G. Sass, J. Zillies, S. Zahler, G. Tiegs, and A. Hartkorn A novel technique for selective NF-kappaB inhibition in Kupffer cells: contrary effects in fulminant hepatitis and ischaemia-reperfusion Gut 58 2009 1670 1678
43. J. Crespo, A. Cayon, P. Fernandez-Gil, M. Hernandez-Guerra, M. Mayorga, and A. Dominguez-Diez Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients Hepatology 34 2001 1158 1163
44. A.B. Alexandroff, A.M. Jackson, M.A. O'Donnell, and K. James BCG immunotherapy of bladder cancer: 20 years on Lancet 353 1999 1689 1694
45. A. Steg, D. Sicard, C. Leleu, B. Debre, and L. Boccon-Gibod Systemic complications of intravesical BCG therapy for bladder cancer Lancet 2 1985 899
46. D.L. Lamm, P.M. van der Meijden, A. Morales, S.A. Brosman, W.J. Catalona, and H.W. Herr Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer J Urol 147 1992 596 600
47. O.Y. Gonzalez, D.M. Musher, I. Brar, S. Furgeson, M.R. Boktour, and E.J. Septimus Spectrum of Bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy Clin Infect Dis 36 2003 140 148